The Keap1–Nrf2 pathway: promising therapeutic target to counteract ROS-mediated damage in cancers and neurodegenerative diseases

Biophysical Reviews

Volumn 9, Issue 1, 2017, Pages 41-56

  Deshmukh, Prashant ^a   Unni, Sruthi ^a   Krishnappa, Gopinatha ^a   Padmanabhan, Balasundaram ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH AND NEUROSCIENCES   (India)

Author keywords

Cancer; Inhibitors; Keap1; Neurodegenerative disorders; Nrf2; Oxidative stress

Indexed keywords

AMIDOPHOSPHORIBOSYLTRANSFERASE; AMYLOID BETA PROTEIN; B RAF KINASE; BAICALEIN; BRUSATOL; CARCINOGEN; CISPLATIN; CURCUMIN; FALCARINDIOL; FUMARIC ACID DIMETHYL ESTER; GANCICLOVIR; GLUCOSE 6 PHOSPHATE DEHYDROGENASE; HUNTINGTIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; ISOCITRATE DEHYDROGENASE 1; KELCH LIKE ECH ASSOCIATED PROTEIN 1; MALATE DEHYDROGENASE (DECARBOXYLATING); METHYLENETETRAHYDROFOLATE DEHYDROGENASE; MYC PROTEIN; PHOSPHOGLUCONATE DEHYDROGENASE; PROTEIN DEGLYCASE DJ-1; PROTHYMOSIN ALPHA; QUERCETIN; REACTIVE OXYGEN METABOLITE; RESVERATROL; SEQUESTOSOME 1; TRANSCRIPTION FACTOR NRF2;

ALZHEIMER DISEASE; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; DEGENERATIVE DISEASE; DRUG DESIGN; EPIGENETICS; GENE SILENCING; HUMAN; HUNTINGTON CHOREA; IMMUNOBLOTTING; INFLAMMATION; ISCHEMIA; LUNG ADENOCARCINOMA; NEOPLASM; NEUROFIBRILLARY TANGLE; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; TUMOR GROWTH;

EID: 85014361638     PISSN: 18672450     EISSN: 18672469     Source Type: Journal    
DOI: 10.1007/s12551-016-0244-4     Document Type: Review

References (130)

1. Adam J, Hatipoglu E, O’Flaherty L, Ternette N, Sahgal N, Lockstone H, Baban D, Nye E, Stamp GW, Wolhuter K, Stevens M (2011) Renal cyst formation in Fh1-deficient mice is independent of the Hif/Phd pathway: roles for fumarate in Keap1 succination and Nrf2 signaling. Cancer Cell 20(4):524–537
2. Adibhatla RM, Hatcher JF (2010) Lipid oxidation and peroxidation in CNS health and disease: from molecular mechanisms to therapeutic opportunities. Antioxid Redox Signal 12(1):125–169
3. Albin RL, Reiner A, Anderson KD, Dure LS, Handelin B, Balfour R, Whetsell WO, Penney JB, Young AB (1992) Preferential loss of striato-external pallidal projection neurons in presymptomatic Huntington’s disease. Ann Neurol 31(4):425–430
4. Albrecht P, Bouchachia I, Goebels N, Henke N, Hofstetter HH, Issberner A, Kovacs Z, Lewerenz J, Lisak D, Maher P, Mausberg AK (2012) Effects of dimethyl fumarate on neuroprotection and immunomodulation. J Neuroinflammation 9(163):2094–2099
5. Ariga H, Takahashi-Niki K, Kato I, Maita H, Niki T, Iguchi-Ariga SM (2013) Neuroprotective function of DJ-1 in Parkinson’s disease. Oxidative Med Cell Longev. doi:10.1155/2013/683920
6. Aronowski J, Zhao X (2011) Molecular pathophysiology of cerebral hemorrhage: secondary brain injury. Stroke 42(6):1781–1786
7. Arrasate M, Mitra S, Schweitzer ES, Segal MR, Finkbeiner S (2004) Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature 431(7010):805–810
8. Bae SH, Sung SH, Oh SY, Lim JM, Lee SK, Park YN, Lee HE, Kang D, Rhee SG (2013) Sestrins activate Nrf2 by promoting p62-dependent autophagic degradation of Keap1 and prevent oxidative liver damage. Cell Metab 17(1):73–84
9. Behl C (2005) Oxidative stress in Alzheimer’s disease: implications for prevention and therapy. Springer, New York, pp 65–78
10. Bouillez A, Rajabi H, Pitroda S, Jin C, Alam M, Kharbanda A, Tagde A, Wong KK, Kufe D (2016) Inhibition of MUC1-C suppresses MYC expression and attenuates malignant growth in KRAS mutant lung adenocarcinomas. Cancer Res 76(6):1538–1548
11. Browne SE, Beal MF (2006) Oxidative damage in Huntington’s disease pathogenesis. Antioxid Redox Signal 8(11–12):2061–2073
12. Bryan HK, Olayanju A, Goldring CE, Park BK (2013) The Nrf2 cell defence pathway: Keap1-dependent and -independent mechanisms of regulation. Biochem Pharmacol 85(6):705–717
13. Calkins MJ, Jakel RJ, Johnson DA, Chan K, Kan YW, Johnson JA (2005) Protection from mitochondrial complex II inhibition in vitro and in vivo by Nrf2-mediated transcription. Proc Natl Acad Sci U S A 102(1):244–249
14. Camp ND, James RG, Dawson DW, Yan F, Davison JM, Houck SA, Tang X, Zheng N, Major MB, Moon RT (2012) Wilms tumor gene on X chromosome (WTX) inhibits degradation of Nrf2 protein through competitive binding to Keap1 protein. J Biol Chem 287(9):6539–6550
15. Canning P, Cooper CD, Krojer T, Murray JW, Pike AC, Chaikuad A, Keates T, Thangaratnarajah C, Hojzan V, Marsden BD, Gileadi O (2013) Structural basis for Cul3 protein assembly with the BTB-Kelch family of E3 ubiquitin ligases. J Biol Chem 288(11):7803–7814
16. Chan JY, Han XL, Kan YW (1993) Cloning of Nrf1, an NF-E2-related transcription factor, by genetic selection in yeast. Proc Natl Acad Sci U S A 90(23):11371–11375
17. Chan JY, Cheung MC, Moi P, Chan K, Kan YW (1995) Chromosomal localization of the human NF-E2 family of bZIP transcription factors by fluorescence in situ hybridization. Hum Genet 95(3):265–269
18. Chauhan N, Chaunsali L, Deshmukh P, Padmanabhan B (2013) Analysis of dimerization of BTB-IVR domains of Keap1 and its interaction with Cul3, by molecular modeling. Bioinformation 9(9):450
19. Chen G, Fang Q, Zhang J, Zhou D, Wang Z (2011) Role of the Nrf2–ARE pathway in early brain injury after experimental subarachnoid hemorrhage. J Neurosci Res 89(4):515–523
20. Cheng IC, Chen YJ, Ku CW, Huang YW, Yang CN (2015) Structural and dynamic characterization of mutated Keap1 for varied affinity toward Nrf2: a molecular dynamics simulation study. J Chem Inf Model 55(10):2178–2186
21. Cho H, Hartsock MJ, Xu Z, He M, Duh EJ (2015) Monomethyl fumarate promotes Nrf2-dependent neuroprotection in retinal ischemia–reperfusion. J Neuroinflammation 12(1):239
22. Cleasby A, Yon J, Day PJ, Richardson C, Tickle IJ, Williams PA, Callahan JF, Carr R, Concha N, Kerns JK, Qi H (2014) Structure of the BTB domain of Keap1 and its interaction with the triterpenoid antagonist CDDO. PLoS One 9(6):e98896
23. Clements CM, McNally RS, Conti BJ, Mak TW, Ting JPY (2006) DJ-1, a cancer- and Parkinson’s disease-associated protein, stabilizes the antioxidant transcriptional master regulator Nrf2. Proc Natl Acad Sci U S A 103(41):15091–15096
24. Cummings JL (2004) Dementia with Lewy bodies: molecular pathogenesis and implications for classification. J Geriatr Psychiatry Neurol 17:112–119
25. Dang J, Brandenburg LO, Rosen C, Fragoulis A, Kipp M, Pufe T, Beyer C, Wruck CJ (2012) Nrf2 expression by neurons, astroglia, and microglia in the cerebral cortical penumbra of ischemic rats. J Mol Neurosci 46(3):578–584
26. de Zeeuw D, Akizawa T, Audhya P, Bakris GL, Chin M, Christ-Schmidt H, Goldsberry A, Houser M, Krauth M, Lambers Heerspink HJ, McMurray JJ; BECON Trial Investigators (2013) Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. N Engl J Med 369:2492–2503
27. DeNicola GM, Karreth FA, Humpton TJ, Gopinathan A, Wei C, Frese K, Mangal D, Kenneth HY, Yeo CJ, Calhoun ES, Scrimieri F (2011) Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature 475(7354):106–109
28. Derjuga A, Gourley TS, Holm TM, Heng HH, Shivdasani RA, Ahmed R, Andrews NC, Blank V (2004) Complexity of CNC transcription factors as revealed by gene targeting of the Nrf3 locus. Mol Cell Biol 24(8):3286–3294
29. Dong T, Liu W, Shen Z, Li L, Chen S, Lei X (2016) Pterisolic acid B is a Nrf2 activator by targeting C171 within Keap1–BTB domain. Sci Rep 6:19231
30. Edwards MR, Johnson B, Mire CE, Xu W, Shabman RS, Speller LN, Leung DW, Geisbert TW, Amarasinghe GK, Basler CF (2014) The Marburg virus VP24 protein interacts with Keap1 to activate the cytoprotective antioxidant response pathway. Cell Rep 6(6):1017–1025
31. Eftekharzadeh B, Maghsoudi N, Khodagholi F (2010) Stabilization of transcription factor Nrf2 by tBHQ prevents oxidative stress-induced amyloid beta formation in NT2N neurons. Biochimie 92(3):245–253
32. Fahey JW, Haristoy X, Dolan PM, Kensler TW, Scholtus I, Stephenson KK, Talalay P, Lozniewski A (2002) Sulforaphane inhibits extracellular, intracellular, and antibiotic-resistant strains of Helicobacter pylori and prevents benzo[a]pyrene-induced stomach tumors. Proc Natl Acad Sci U S A 99(11):7610–7615
33. Faraonio R, Vergara P, Di Marzo D, Pierantoni MG, Napolitano M, Russo T, Cimino F (2006) p53 suppresses the Nrf2-dependent transcription of antioxidant response genes. J Biol Chem 281(52):39776–39784
34. Feigin VL, Rinkel GJ, Lawes CM, Algra A, Bennett DA, van Gijn J, Anderson CS (2005) Risk factors for subarachnoid hemorrhage: an updated systematic review of epidemiological studies. Stroke 36(12):2773–2780
35. Filippin LI, Vercelino R, Marroni NP, Xavier RM (2008) Redox signalling and the inflammatory response in rheumatoid arthritis. Clin Exp Immunol 152(3):415–422
36. Flamm ES, Demopoulos HB, Seligman ML, Poser RG, Ransohoff JO (1978) Free radicals in cerebral ischemia. Stroke 9(5):445–447
37. Furfaro AL, Macay JRZ, Marengo B, Nitti M, Parodi A, Fenoglio D, Marinari UM, Pronzato MA, Domenicotti C, Traverso N (2012) Resistance of neuroblastoma GI-ME-N cell line to glutathione depletion involves Nrf2 and heme oxygenase-1. Free Radic Biol Med 52(2):488–496
38. Furukawa M, Xiong Y (2005) BTB protein Keap1 targets antioxidant transcription factor Nrf2 for ubiquitination by the Cullin 3-Roc1 ligase. Mol Cell Biol 25(1):162–171
39. Hancock R, Schaap M, Pfister H, Wells G (2013) Peptide inhibitors of the Keap1–Nrf2 protein–protein interaction with improved binding and cellular activity. Org Biomol Chem 11(21):3553–3557
40. Hasegawa M, Takahashi H, Rajabi H, Alam M, Suzuki Y, Yin L, Tagde A, Maeda T, Hiraki M, Sukhatme VP, Kufe D (2016) Functional interactions of the cystine/glutamate antiporter, CD44v and MUC1-C oncoprotein in triple-negative breast cancer cells. Oncotarget 7(11):11756–11769
41. Hu L, Magesh S, Chen L, Wang L, Lewis TA, Chen Y, Khodier C, Inoyama D, Beamer LJ, Emge TJ, Shen J (2013) Discovery of a small-molecule inhibitor and cellular probe of Keap1–Nrf2 protein–protein interaction. Bioorg Med Chem Lett 23(10):3039–3043
42. Itoh K, Wakabayashi N, Katoh Y, Ishii T, Igarashi K, Engel JD, Yamamoto M (1999) Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain. Genes Dev 13(1):76–86
43. Jakel RJ, Kern JT, Johnson DA, Johnson JA (2005) Induction of the protective antioxidant response element pathway by 6-hydroxydopamine in vivo and in vitro. Toxicol Sci 87(1):176–186
44. Jaramillo MC, Zhang DD (2013) The emerging role of the Nrf2–Keap1 signaling pathway in cancer. Genes Dev 27(20):2179–2191
45. Jiang Z, Duong TQ (2016) Methylene blue treatment in experimental ischemic stroke: a mini review. Brain Circ 2(1):48–53
46. Jiang ZY, Chu HX, Xi MY, Yang TT, Jia JM, Huang JJ, Guo XK, Zhang XJ, You QD, Sun HP (2013) Insight into the intermolecular recognition mechanism between Keap1 and IKKβ combining homology modelling, protein–protein docking, molecular dynamics simulations and virtual alanine mutation. PLoS One 8(9):e75076
47. Jiang ZY, Xu LL, Lu MC, Chen ZY, Yuan ZW, Xu XL, Guo XK, Zhang XJ, Sun HP, You QD (2015) Structure–activity and structure–property relationship and exploratory in vivo evaluation of the nanomolar Keap1–Nrf2 protein–protein interaction inhibitor. J Med Chem 58(16):6410–6421
48. Jiang S, Deng C, Lv J, Fan C, Hu W, Di S, Yan X, Ma Z, Liang Z, Yang Y (2016) Nrf2 weaves an elaborate network of neuroprotection against stroke. Mol Neurobiol 1–16
49. Kansanen E, Kuosmanen SM, Leinonen H, Levonen AL (2013) The Keap1–Nrf2 pathway: mechanisms of activation and dysregulation in cancer. Redox Biol 1(1):45–49
50. Kensler TW, Wakabayashi N (2010) Nrf2: friend or foe for chemoprevention? Carcinogenesis 31(1):90–99
51. Khor TO, Fuentes F, Shu L, Paredes-Gonzalez X, Yang AY, Liu Y, Smiraglia DJ, Yegnasubramanian S, Nelson WG, Kong ANT (2014) Epigenetic DNA methylation of antioxidative stress regulator Nrf2 in human prostate cancer. Cancer Prev Res 7(12):1186–1197
52. Kim JE, You DJ, Lee C, Ahn C, Seong JY, Hwang JI (2010a) Suppression of NF-κB signaling by KEAP1 regulation of IKKβ activity through autophagic degradation and inhibition of phosphorylation. Cell Signal 22(11):1645–1654
53. Kim YR, Oh JE, Kim MS, Kang MR, Park SW, Han JY, Eom HS, Yoo NJ, Lee SH (2010b) Oncogenic NRF2 mutations in squamous cell carcinomas of oesophagus and skin. J Pathol 220(4):446–451
54. Kobayashi A, Kang MI, Okawa H, Ohtsuji M, Zenke Y, Chiba T, Igarashi K, Yamamoto M (2004) Oxidative stress sensor Keap1 functions as an adaptor for Cul3-based E3 ligase to regulate proteasomal degradation of Nrf2. Mol Cell Biol 24(16):7130–7139
55. Komatsu M, Kurokawa H, Waguri S, Taguchi K, Kobayashi A, Ichimura Y, Sou YS, Ueno I, Sakamoto A, Tong KI, Kim M (2010) The selective autophagy substrate p62 activates the stress responsive transcription factor Nrf2 through inactivation of Keap1. Nat Cell Biol 12(3):213–223
56. Kontos HA (1989) Oxygen radicals in CNS damage. Chem Biol Interact 72(3):229–255
57. Kraft AD, Johnson DA, Johnson JA (2004) Nuclear factor E2-related factor 2-dependent antioxidant response element activation by tert-butylhydroquinone and sulforaphane occurring preferentially in astrocytes conditions neurons against oxidative insult. J Neurosci 24(5):1101–1112
58. Lau A, Villeneuve NF, Sun Z, Wong PK, Zhang DD (2008) Dual roles of Nrf2 in cancer. Pharmacol Res 58(5):262–270
59. Lau A, Wang XJ, Zhao F, Villeneuve NF, Wu T, Jiang T, Sun Z, White E, Zhang DD (2010) A noncanonical mechanism of Nrf2 activation by autophagy deficiency: direct interaction between Keap1 and p62. Mol Cell Biol 30(13):3275–3285
60. Lee Y, Shin DH, Kim JH, Hong S, Choi D, Kim YJ, Kwak MK, Jung Y (2010) Caffeic acid phenethyl ester-mediated Nrf2 activation and IκB kinase inhibition are involved in NFκB inhibitory effect: structural analysis for NFκB inhibition. Eur J Pharmacol 643(1):21–28
61. Leinonen HM, Ruotsalainen AK, Määttä AM, Laitinen HM, Kuosmanen SM, Kansanen E, Pikkarainen JT, Lappalainen JP, Samaranayake H, Lesch HP, Kaikkonen MU (2012) Oxidative stress-regulated lentiviral TK/GCV gene therapy for lung cancer treatment. Cancer Res 72(23):6227–6235
62. Leirós M, Alonso E, Sanchez JA, Rateb ME, Ebel R, Houssen WE, Jaspars M, Alfonso A, Botana LM (2013) Mitigation of ROS insults by streptomyces secondary metabolites in primary cortical neurons. ACS Chem Neurosci 5(1):71–80
63. Levy S, Forman HJ (2010) C‐Myc is a Nrf2‐interacting protein that negatively regulates phase II genes through their electrophile responsive elements. IUBMB Life 62(3):237–246
64. Li W, Zheng S, Higgins M, Morra RP Jr, Mendis AT, Chien CW, Ojima I, Mierke DF, Dinkova-Kostova AT, Honda T (2015) New monocyclic, bicyclic, and tricyclic ethynylcyanodienones as activators of the Keap1/Nrf2/ARE pathway and inhibitors of inducible nitric oxide synthase. J Med Chem 58(11):4738–4748
65. Linker RA, Lee DH, Ryan S, van Dam AM, Conrad R, Bista P, Zeng W, Hronowsky X, Buko A, Chollate S, Ellrichmann G (2011) Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway. Brain 134(3):678–692
66. Magesh S, Chen Y, Hu L (2012) Small molecule modulators of Keap1–Nrf2–ARE pathway as potential preventive and therapeutic agents. Med Res Rev 32(4):687–726
67. Marcotte D, Zeng W, Hus JC, McKenzie A, Hession C, Jin P, Bergeron C, Lugovskoy A, Enyedy I, Cuervo H, Wang D (2013) Small molecules inhibit the interaction of Nrf2 and the Keap1 Kelch domain through a non-covalent mechanism. Bioorg Med Chem 21(14):4011–4019
68. Marcus DL, Thomas C, Rodriguez C, Simberkoff K, Tsai JS, Strafaci JA, Freedman ML (1998) Increased peroxidation and reduced antioxidant enzyme activity in Alzheimer’s disease. Exp Neurol 150(1):40–44
69. Marzec JM, Christie JD, Reddy SP, Jedlicka AE, Vuong H, Lanken PN, Aplenc R, Yamamoto T, Yamamoto M, Cho HY, Kleeberger SR (2007) Functional polymorphisms in the transcription factor Nrf2 in humans increase the risk of acute lung injury. FASEB J 21(9):2237–2246
70. McMahon M, Thomas N, Itoh K, Yamamoto M, Hayes JD (2004) Redox-regulated turnover of Nrf2 is determined by at least two separate protein domains, the redox-sensitive Neh2 degron and the redox-insensitive Neh6 degron. J Biol Chem 279(30):31556–31567
71. Mercado N, Kizawa Y, Ueda K, Xiong Y, Kimura G, Moses A, Curtis JM, Ito K, Barnes PJ (2014) Activation of transcription factor Nrf2 signalling by the sphingosine kinase inhibitor SKI-II is mediated by the formation of Keap1 dimers. PLoS One 9(2):e88168
72. Mitsuishi Y, Taguchi K, Kawatani Y, Shibata T, Nukiwa T, Aburatani H, Yamamoto M, Motohashi H (2012) Nrf2 redirects glucose and glutamine into anabolic pathways in metabolic reprogramming. Cancer Cell 22(1):66–79
73. Moi P, Chan K, Asunis I, Cao A, Kan YW (1994) Isolation of NF-E2-related factor 2 (Nrf2), a NF-E2-like basic leucine zipper transcriptional activator that binds to the tandem NF-E2/AP1 repeat of the beta-globin locus control region. Proc Natl Acad Sci U S A 91(21):9926–9930
74. Morito N, Yoh K, Itoh K, Hirayama A, Koyama A, Yamamoto M, Takahashi S (2003) Nrf2 regulates the sensitivity of death receptor signals by affecting intracellular glutathione levels. Oncogene 22(58):9275–9281
75. Mosley RL, Benner EJ, Kadiu I, Thomas M, Boska MD, Hasan K, Laurie C, Gendelman HE (2006) Neuroinflammation, oxidative stress, and the pathogenesis of Parkinson’s disease. Clin Neurosci Res 6(5):261–281
76. Motohashi H, O’Connor T, Katsuoka F, Engel JD, Yamamoto M (2002) Integration and diversity of the regulatory network composed of Maf and CNC families of transcription factors. Gene 294(1):1–12
77. Muscarella LA, Parrella P, D’Alessandro V, la Torre A, Barbano R, Fontana A, Tancredi A, Guarnieri V, Balsamo T, Coco M, Copetti M (2011) Frequent epigenetics inactivation of KEAP1 gene in non-small cell lung cancer. Epigenetics 6(6):710–719
78. Nioi P, Nguyen T, Sherratt PJ, Pickett CB (2005) The carboxy-terminal Neh3 domain of Nrf2 is required for transcriptional activation. Mol Cell Biol 25(24):10895–10906
79. Niture SK, Jaiswal AK (2010) Hsp90 interaction with INrf2 (Keap1) mediates stress-induced Nrf2 activation. J Biol Chem 285(47):36865–36875
80. Ohnuma T, Nakayama S, Anan E, Nishiyama T, Ogura K, Hiratsuka A (2010) Activation of the Nrf2/ARE pathway via S-alkylation of cysteine 151 in the chemopreventive agent-sensor Keap1 protein by falcarindiol, a conjugated diacetylene compound. Toxicol Appl Pharmacol 244(1):27–36
81. Ooi A, Dykema K, Ansari A, Petillo D, Snider J, Kahnoski R, Anema J, Craig D, Carpten J, Teh BT, Furge KA (2013) CUL3 and Nrf2 mutations confer an Nrf2 activation phenotype in a sporadic form of papillary renal cell carcinoma. Cancer Res 73(7):2044–2051
82. Osburn WO, Karim B, Dolan PM, Liu G, Yamamoto M, Huso DL, Kensler TW (2007) Increased colonic inflammatory injury and formation of aberrant crypt foci in Nrf2-deficient mice upon dextran sulfate treatment. Int J Cancer 121(9):1883–1891
83. Padmanabhan B, Tong KI, Ohta T, Nakamura Y, Scharlock M, Ohtsuji M, Kang MI, Kobayashi A, Yokoyama S, Yamamoto M (2006) Structural basis for defects of Keap1 activity provoked by its point mutations in lung cancer. Mol Cell 21(5):689–700
84. Padmanabhan B, Nakamura Y, Yokoyama S (2008) Structural analysis of the complex of Keap1 with a prothymosin α peptide. Acta Crystallogr Sect F: Struct Biol Cryst Commun 64(4):233–238
85. Pang C, Zheng Z, Shi L, Sheng Y, Wei H, Wang Z, Ji L (2016) Caffeic acid prevents acetaminophen-induced liver injury by activating the Keap1–Nrf2 antioxidative defense system. Free Radic Biol Med 91:236–246
86. Park JS, Kang DH, Bae SH (2015) PF-4708671, a specific inhibitor of p70 ribosomal S6 kinase 1, activates Nrf2 by promoting p62-dependent autophagic degradation of Keap1. Biochem Biophys Res Commun 466(3):499–504
87. Qin S, Deng F, Wu W, Jiang L, Yamashiro T, Yano S, Hou DX (2014) Baicalein modulates Nrf2/Keap1 system in both Keap1-dependent and Keap1-independent mechanisms. Arch Biochem Biophys 559:53–61
88. Rajabi H, Tagde A, Alam M, Bouillez A, Pitroda S, Suzuki Y, Kufe D (2016) DNA methylation by DNMT1 and DNMT3b methyltransferases is driven by the MUC1-C oncoprotein in human carcinoma cells. Oncogene. doi:10.1038/onc.2016.180
89. Ramos-Gomez M, Kwak MK, Dolan PM, Itoh K, Yamamoto M, Talalay P, Kensler TW (2001) Sensitivity to carcinogenesis is increased and chemoprotective efficacy of enzyme inducers is lost in Nrf2 transcription factor-deficient mice. Proc Natl Acad Sci U S A 98(6):3410–3415
90. Ramsey CP, Glass CA, Montgomery MB, Lindl KA, Ritson GP, Chia LA, Hamilton RL, Chu CT, Jordan-Sciutto KL (2007) Expression of Nrf2 in neurodegenerative diseases. J Neuropathol Exp Neurol 66(1):75–85
91. Ren J, Fan C, Chen N, Huang J, Yang Q (2011) Resveratrol pretreatment attenuates cerebral ischemic injury by upregulating expression of transcription factor Nrf2 and HO-1 in rats. Neurochem Res 36(12):2352–2362
92. Riedl AG, Watts PM, Brown CT, Jenner P (1999) P450 and heme oxygenase enzymes in the basal ganglia and their roles in Parkinson’s disease. Adv Neurol 80:271–286
93. Saha A, Deshaies RJ (2008) Multimodal activation of the ubiquitin ligase SCF by Nedd8 conjugation. Mol Cell 32(1):21–31
94. Saifee NH, Zheng N (2008) A ubiquitin-like protein unleashes ubiquitin ligases. Cell 135(2):209–211
95. Schipper HM, Bennett DA, Liberman A, Bienias JL, Schneider JA, Kelly J, Arvanitakis Z (2006) Glial heme oxygenase-1 expression in Alzheimer disease and mild cognitive impairment. Neurobiol Aging 27(2):252–261
96. Sekhar KR, Yan XX, Freeman ML (2002) Nrf2 degradation by the ubiquitin proteasome pathway is inhibited by KIAA0132, the human homolog to INrf2. Oncogene 21(44):6829–6834
97. Shibata T, Kokubu A, Gotoh M, Ojima H, Ohta T, Yamamoto M, Hirohashi S (2008a) Genetic alteration of Keap1 confers constitutive Nrf2 activation and resistance to chemotherapy in gallbladder cancer. Gastroenterology 135(4):1358–1368
98. Shibata T, Ohta T, Tong KI, Kokubu A, Odogawa R, Tsuta K, Asamura H, Yamamoto M, Hirohashi S (2008b) Cancer related mutations in NRF2 impair its recognition by Keap1–Cul3 E3 ligase and promote malignancy. Proc Natl Acad Sci U S A 105(36):13568–13573
99. Shibata T, Kokubu A, Saito S, Narisawa-Saito M, Sasaki H, Aoyagi K, Yoshimatsu Y, Tachimori Y, Kushima R, Kiyono T, Yamamoto M (2011) NRF2 mutation confers malignant potential and resistance to chemoradiation therapy in advanced esophageal squamous cancer. Neoplasia 13(9):864–873
100. Shih AY, Johnson DA, Wong G, Kraft AD, Jiang L, Erb H, Johnson JA, Murphy TH (2003) Coordinate regulation of glutathione biosynthesis and release by Nrf2-expressing glia potently protects neurons from oxidative stress. J Neurosci 23(8):3394–3406
101. Singh A, Misra V, Thimmulappa RK, Lee H, Ames S, Hoque MO, Herman JG, Baylin SB, Sidransky D, Gabrielson E, Brock MV (2006) Dysfunctional KEAP1–NRF2 interaction in non-small-cell lung cancer. PLoS Med 3(10):e420
102. Sirota R, Gibson D, Kohen R (2015) The role of the catecholic and the electrophilic moieties of caffeic acid in Nrf2/Keap1 pathway activation in ovarian carcinoma cell lines. Redox Biol 4:48–59
103. Slocum SL, Kensler TW (2011) Nrf2: control of sensitivity to carcinogens. Arch Toxicol 85(4):273–284
104. Son TG, Camandola S, Mattson MP (2008) Hormetic dietary phytochemicals. Neuromol Med 10(4):236–246
105. Stogios PJ, Privé GG (2004) The BACK domain in BTB-kelch proteins. Trends Biochem Sci 29(12):634–637
106. Sugamura K, Keaney JF Jr (2011) Reactive oxygen species in cardiovascular disease. Free Radic Biol Med 51(5):978–992
107. Sun Z, Wu T, Zhao F, Lau A, Birch CM, Zhang DD (2011) KPNA6 (Importin α7)-mediated nuclear import of Keap1 represses the Nrf2-dependent antioxidant response. Mol Cell Biol 31(9):1800–1811
108. Tagde A, Singh H, Kang MH, Reynolds CP (2014) The glutathione synthesis inhibitor buthionine sulfoximine synergistically enhanced melphalan activity against preclinical models of multiple myeloma. Blood Cancer J 4:e229
109. Tagde A, Rajabi H, Bouillez A, Alam M, Gali R, Bailey S, Tai YT, Hideshima T, Anderson K, Avigan D, Kufe D (2016a) MUC1-C drives MYC in multiple myeloma. Blood 127(21):2587–2597
110. Tagde A, Rajabi H, Stroopinsky D, Gali R, Alam M, Bouillez A, Kharbanda S, Stone R, Avigan D, Kufe D (2016b) MUC1-C induces DNA methyltransferase 1 and represses tumor suppressor genes in acute myeloid leukemia. Oncotarget. doi:10.18632/oncotarget.9777
111. Taguchi K, Motohashi H, Yamamoto M (2011) Molecular mechanisms of the Keap1–Nrf2 pathway in stress response and cancer evolution. Genes Cells 16(2):123–140
112. Takahashi H, Jin C, Rajabi H, Pitroda S, Alam M, Ahmad R, Raina D, Hasegawa M, Suzuki Y, Tagde A, Bronson RT (2015) MUC1-C activates the TAK1 inflammatory pathway in colon cancer. Oncogene 34(40):5187–5197
113. Tanigawa S, Fujii M, Hou DX (2007) Action of Nrf2 and Keap1 in ARE-mediated NQO1 expression by quercetin. Free Radic Biol Med 42(11):1690–1703
114. Tayek JA, Kalantar-Zadeh K (2013) The extinguished BEACON of bardoxolone: not a Monday morning quarterback story. Am J Nephrol 37(3):208–211
115. Tong KI, Padmanabhan B, Kobayashi A, Shang C, Hirotsu Y, Yokoyama S, Yamamoto M (2007) Different electrostatic potentials define ETGE and DLG motifs as hinge and latch in oxidative stress response. Mol Cell Biol 27(21):7511–7521
116. Turrens JF (2003) Mitochondrial formation of reactive oxygen species. J Physiol 552(2):335–344
117. Venci JV, Gandhi MA (2013) Dimethyl fumarate (Tecfidera): a new oral agent for multiple sclerosis. Ann Pharmacother 47(12):1697–1702
118. Walker FO (2007) Huntington’s disease. Lancet 369(9557):218–228
119. Wang R, An J, Ji F, Jiao H, Sun H, Zhou D (2008) Hypermethylation of the Keap1 gene in human lung cancer cell lines and lung cancer tissues. Biochem Biophys Res Commun 373(1):151–154
120. Wang W, Kang J, Li H, Su J, Wu J, Xu Y, Yu H, Xiang X, Yi H, Lu Y, Sun L (2013) Regulation of endoplasmic reticulum stress in rat cortex by p62/ZIP through the Keap1–Nrf2–ARE signalling pathway after transient focal cerebral ischaemia. Brain Inj 27(7–8):924–933
121. Xu H, Zhou YL, Zhang XY, Lu P, Li GS (2010) Activation of PERK signaling through fluoride-mediated endoplasmic reticulum stress in OS732 cells. Toxicology 277(1):1–5
122. Yamazaki H, Tanji K, Wakabayashi K, Matsuura S, Itoh K (2015) Role of the Keap1/Nrf2 pathway in neurodegenerative diseases. Pathol Int 65(5):210–219
123. Yang C, Zhang X, Fan H, Liu Y (2009) Curcumin upregulates transcription factor Nrf2, HO-1 expression and protects rat brains against focal ischemia. Brain Res 1282:133–141
124. Yu X, Kensler T (2005) Nrf2 as a target for cancer chemoprevention. Mutat Res 591(1–2):93–102
125. Yu S, Khor TO, Cheung KL, Li W, Wu TY, Huang Y, Foster BA, Kan YW, Kong AN (2010) Nrf2 expression is regulated by epigenetic mechanisms in prostate cancer of TRAMP mice. PLoS One 5(1):e8579
126. Zhang DD (2013) Bardoxolone brings Nrf2-based therapies to light. Antioxid Redox Signal 19(5):517–518
127. Zhang M, An C, Gao Y, Leak RK, Chen J, Zhang F (2013) Emerging roles of Nrf2 and phase II antioxidant enzymes in neuroprotection. Prog Neurobiol 100:30–47
128. Zhao X, Sun G, Zhang J, Strong R, Dash PK, Kan YW, Grotta JC, Aronowski J (2007) Transcription factor Nrf2 protects the brain from damage produced by intracerebral haemorrhage. Stroke 38(12):3280–3286
129. Zhuang C, Narayanapillai S, Zhang W, Sham YY, Xing C (2014) Rapid identification of Keap1–Nrf2 small-molecule inhibitors through structure-based virtual screening and hit-based substructure search. J Med Chem 57(3):1121–1126
130. Zipper LM, Mulcahy RT (2002) The Keap1 BTB/POZ dimerization function is required to sequester Nrf2 in cytoplasm. J Biol Chem 277(39):36544–36552